Biofront Therapeutics (Beijing) Co. Ltd. has prepared and tested cathepsin L (CTSL) inhibitors potentially useful for the treatment of acute respiratory distress syndrome (ARDS), cancer, diabetes, liver injury, viral infections and bone, inflammatory and renal disorders, among others.